Trial Search Results

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies

To measure how frequently and to what degree a complication of transplant cell acute graft versus host disease (GvHD) occurs.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University


  • Drug: Cyclosporine
  • Drug: Anti-thymocyte globulin (ATG)
  • Drug: Mycophenolate mofetil (MMF)
  • Drug: Filgrastim
  • Radiation: Total Lymphoid Irradiation (TLI)


Phase 2



   - Any patient with one of the following hematolymphoid malignancies or syndromes in whom
   allogeneic hematopoietic stem cell transplant (HST) is warranted. Specific disease
   categories include:

      - Indolent advanced stage non-Hodgkin lymphomas

      - Mantle cell lymphoma

      - Chronic lymphocytic leukemia

      - Hodgkin disease (Hodgkin's lymphoma)

      - Acute leukemias in complete remission

      - Aplastic anemia

      - Paroxysmal nocturnal hemoglobinuria

      - Myelodysplastic or myeloproliferative syndromes.

      - Other selected malignancies/disorders may also be considered but must be approved
      by the transplant team and the Principal Investigator.

   - Age > 50 years, or if < 50 years of age, considered to be at high risk for
   regimen-related toxicity associated with conventional myeloablative transplants due to
   pre-existing medical conditions or prior therapy.

   - A fully human leukocyte antigen (HLA)-identical sibling or matched unrelated donor is
   available. Potential participants with one antigen mismatched donors can be considered
   but only after discussion with the transplant team and the Principal Investigator.

   - Participant must be competent to give consent.


   - Progressive hematolymphoid malignancies despite conventional therapies, or acute
   leukemias not in complete remission.

   - Uncontrolled central nervous system (CNS) involvement with disease

   - Fertile men or women unwilling to use contraceptive techniques during and for 12
   months following treatment

   - Pregnant

   - Cardiac ejection fraction < 30%

   - Uncontrolled cardiac failure

   - Pulmonary diffusing capacity (DLCO) < 40% predicted

   - Elevation of bilirubin to > 3 mg/dL

   - Transaminases > 4 x the upper limit of normal

   - Creatinine clearance < 50 cc/min (24-hour urine collection)

   - Karnofsky performance score < 60%

   - Poorly controlled hypertension on multiple antihypertensives

   - Documented fungal disease that is progressive despite treatment

   - HIV-positive. Other viral infections, ie, Hepatitis B- and C- positive, evaluated on a
   case-by-case basis

   - Psychiatric disorders or psychosocial problems which in the opinion of the primary
   physician or Principal Investigator would place the patient at unacceptable risk from
   this regimen.

Ages Eligible for Study

50 Years - 70 Years

Genders Eligible for Study